Barriers to Initiation of Antiretroviral Treatment in Rural and Urban Areas of Zambia: A Cross-Sectional Study of Cost, Stigma, and Perceptions about ART by Fox, Matthew P. et al.
Boston University
OpenBU http://open.bu.edu
Center for Global Health and Development Center for Global Health and Development Papers
2010-3-6
Barriers to Initiation of
Antiretroviral Treatment in Rural
and Urban Areas of Zambia: A
Cross-Sectional Study of Cost,
Stigma, and Perceptions about ART
Fox, Matthew P, Arthur Mazimba, Phil Seidenberg, Denise Crooks, Bornwell Sikateyo,
Sydney Rosen. "Barriers to initiation of antiretroviral treatment in rural and urban
areas of Zambia: a cross-sectional study of cost, stigma, and perceptions about
ART" Journal of the International AIDS Society 13:8. (2010)
https://hdl.handle.net/2144/3235
Boston University
RESEARCH Open Access
Barriers to initiation of antiretroviral treatment in
rural and urban areas of Zambia: a cross-sectional
study of cost, stigma, and perceptions about ART
Matthew P Fox1*, Arthur Mazimba2, Phil Seidenberg1,2, Denise Crooks3, Bornwell Sikateyo4, Sydney Rosen1
Abstract
Background: While the number of HIV-positive patients on antiretroviral therapy (ART) in resource-limited settings
has increased dramatically, some patients eligible for treatment do not initiate ART even when it is available to
them. Understanding why patients opt out of care, or are unable to opt in, is important to achieving the goal of
universal access.
Methods: We conducted a cross-sectional survey among 400 patients on ART (those who were able to access
care) and 400 patients accessing home-based care (HBC), but who had not initiated ART (either they were not able
to, or chose not to, access care) in two rural and two urban sites in Zambia to identify barriers to and facilitators of
ART uptake.
Results: HBC patients were 50% more likely to report that it would be very difficult to get to the ART clinic than
those on ART (RR: 1.48; 95% CI: 1.21-1.82). Stigma was common in all areas, with 54% of HBC patients, but only
15% of ART patients, being afraid to go to the clinic (RR: 3.61; 95% CI: 3.12-4.18). Cost barriers differed by location:
urban HBC patients were three times more likely to report needing to pay to travel to the clinic than those on ART
(RR: 2.84; 95% CI: 2.02-3.98) and 10 times more likely to believe they would need to pay a fee at the clinic (RR: 9.50;
95% CI: 2.24-40.3). In rural areas, HBC subjects were more likely to report needing to pay non-transport costs to
attend the clinic than those on ART (RR: 4.52; 95% CI: 1.91-10.7). HBC patients were twice as likely as ART patients
to report not having enough food to take ART being a concern (27% vs. 13%, RR: 2.03; 95% CI: 1.71-2.41),
regardless of location and gender.
Conclusions: Patients in home-based care for HIV/AIDS who never initiated ART perceived greater financial and
logistical barriers to seeking HIV care and had more negative perceptions about the benefits of the treatment.
Future efforts to expand access to antiretroviral care should consider ways to reduce these barriers in order to
encourage more of those medically eligible for antiretrovirals to initiate care.
Background
It has been estimated that globally about 4 million HIV-
positive people were on antiretroviral therapy (ART) at
the end of 2008 [1]. In resource-limited settings, the
number on treatment has increased dramatically since
the large-scale roll out of ART. Despite the ever-increas-
ing availability of ART in these settings, however, some
patients eligible for treatment do not initiate ART even
when it is available to them.
In Zambia, where national adult HIV prevalence is
estimated at 14% to 16% [2,3], only between 50% and
66% of those in need of ART were accessing it as of
2007 [4,5]. Some of those who are not in care have
deliberately opted not to seek it, while others lack the
resources, information or motivation required to do so.
Understanding why patients opt out of care, or are
unable to opt in, is important to achieving the goal of
universal access. Currently, little is known about what
inhibits uptake of antiretroviral (ARV) treatment even
when it is available to them.
The majority of research on barriers to accessing ART
has been conducted in resource-rich environments
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[6-12], and has identified poverty, fear of side effects
[7,9], lack of belief in the need for treatment [8], and
fear of stigma [10] as important barriers. In resource-
limited settings, where barriers to accessing care likely
differ [13], far less research has been conducted. Rea-
sons for not seeking available care in resource-limited
settings are likely related to the cost of seeking treat-
ment [14-16], the time and distance needed to travel to
access care [17], stigma [14], fear of violence [18,19],
and reliance on traditional medicine [20].
While some research has been conducted to identify
these barriers, we have found no published quantitative
studies in developing countries that have compared
actual and perceived barriers to accessing ART between
those who chose to initiate treatment and successfully
accessed care and those who did not. This lack of a
comparison makes it difficult to identify which factors
have the strongest influence on treatment seeking and
could be targeted to improve uptake. To understand
why HIV-positive people who are medically eligible for
ART do not initiate treatment, we surveyed patients on
ART and patients believed to be accessing home-based
care for HIV/AIDS, but who had not initiated ART, to
identify barriers to and facilitators of ART uptake in
rural and urban areas of Zambia.
Methods
Study sites
The study sites were HIV clinics and the surrounding
catchment areas. Two sites were located in Zambia’s
Southern Province, one in an urban area in Livingstone
(Maramba clinic), and one in a rural part of Choma Dis-
trict (Pemba clinic). A third site was urban and located
in Lusaka (Chawama clinic) in Lusaka Province, and the
fourth was in a rural part of Central Province in Chi-
bombo (Chipembi Mission Clinic). All the sites, except
Chipembi, were government clinics.
The HIV prevalence in the study areas ranged from
14% in Southern Province to as high as 21% in Lusaka
[2]. HIV treatment providers serving the sites were
vastly different in size, but all were government clinics
offering ART, prevention of mother to child transmis-
sion services, and voluntary counselling and testing. The
rural sites each had between 400 and 600 active patients
on ART, while the urban sites had between 2000 and
8000 patients on ART.
Within the catchment area of each study site clinic,
we identified a home-based care programme that was
providing services to patients who have terminal condi-
tions, including confirmed and suspected HIV-positive
patients who chose not to initiate ART. Home-based
care (HBC) is provided by faith-based and other non-
governmental organizations (NGOs) in Zambia; it offers
palliative care to people in advanced stages of HIV.
Three of the HBC groups were operating under the gov-
ernment clinic, while the fourth was NGO run.
Study design and population
We conducted a cross-sectional survey by administering
a questionnaire among confirmed and suspected HIV-
positive adults (≥ 18 years old) believed to be medically
eligible for ART (i.e., with CD4 counts of <200 cells/mm3
or WHO stage III/IV [21]) at two rural and two urban
sites in Zambia. Eligible subjects were those living within
the catchment area of the ART clinic and were eligible
for ART. To be able to identify barriers to seeking ART,
we enrolled two groups of subjects: (1) clients of one or
more home-based AIDS care programmes; and (2)
patients on ART at the HIV clinics serving the same
populations as the HBC programmes.
Our primary focus was on patients who were eligible
for ART, but who chose not to initiate HIV treatment.
Individuals who choose not to initiate ART are difficult
to access as they do not present at a facility for HIV
care. One way to identify HIV-infected people not on
ART is through home-based care organizations, which
care for patients in the community as they become ill.
HBC programmes encourage eligible subjects to initiate
ART, but also provide palliative care for those who
decline. Thus, by working with HBC programmes to
enrol HBC patients, we were able to select a sample of
ill patients who had chosen not to initiate ART.
Subjects in the HBC group comprised individuals
believed by HBC caregivers to be medically eligible for
ARV treatment, but not actively on treatment. We
excluded all HBC subjects who were on ART, as well as
subjects who had received ARVs prior to study enrol-
ment. Because this population is difficult to identify and
because we wished to respect patients’ decisions and
attitudes towards treatment, we relied on HBC care-
givers to identify eligible subjects. It is possible that
some of these subjects were using HBC services for
non-HIV-related conditions as an HIV diagnosis is not
required for HBC care. However, we asked HBC staff to
refer to our study only those patients who had been
screened for ART eligibility using WHO staging.
Comparison subjects are those actively on ART and
represent the population able to access ARV treatment.
For comparability, we enrolled subjects receiving HIV
care from the clinic serving the same catchment areas
as those of the HBC programmes. We limited this popu-
lation to subjects on ART for at least three months
because there is a relatively high attrition from ARV
programmes in the first three months, and subjects who
did not remain on ART beyond three months would
not be an appropriate group to represent those who
were able to access care [22]. We further limited the
comparison population to those on ART for less than
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six months to maximize their ability to recall events at
the time of the decision to begin treatment.
Data collection
HBC subjects were interviewed at home by a trained
interviewer accompanied by an HBC caregiver. Any sub-
ject in the HBC group who expressed an interest in
initiating HIV treatment was referred to the local HIV
clinic with assistance from the HBC programme. ARV
subjects were screened for eligibility by clinic nurses
from the list of all registered patients and selected with
nth name sampling. Eligible subjects willing to be inter-
viewed were referred to a trained interviewer, who con-
ducted the interview during a routine clinic visit.
Questions were phrased differently for those in the
HBC group and those in the ARV group. Typically,
HBC subjects were asked hypothetical questions, while
ARV subjects were asked about their actual experience.
For example, ARV subjects were asked about the trans-
portation they actually took to the HIV clinic or what
concerns they had about taking ART, while HBC sub-
jects were asked about what transportation they thought
they would use to get to the HIV clinic or what con-
cerns people have about taking ART.
All subjects gave verbal consent to be interviewed.
The study was approved by the Boston University Insti-
tutional Review Board and the University of Zambia
Research Ethics Committee.
Analytic variables and statistical analysis
We asked subjects about transportation to the clinic
(mode, time and costs) and their concerns about ART
at the time they were considering initiating ART. Sub-
jects in the HBC group who had never actively decided
to forgo ART were asked about their current concerns.
Concerns were categorized as being about: (1) fear/
stigma; (2) perceived benefits of ARVs; (3) harms of
and/or difficulties with ARVs; (4) need for ARVs; and
(5) barriers to accessing ARVs. We present the results
as simple percentages and relative risks (RR) and corre-
sponding 95% confidence intervals (CI). To look for dif-
ferences in barriers to care seeking by site, we stratified
our analyses by location (rural or urban). Where strong
differences were found, we also analyzed data stratified
by gender (data not shown).
Results
Socio-economic and demographic characteristics
We surveyed 800 subjects evenly distributed between
study sites and between subjects on ART and those in
home-based care (Table 1). About two in three subjects
were female and more than half were between 20 and
39 years of age, similar to the distribution of all patients
on ART in Zambia.
Those interviewed were generally of low socio-eco-
nomic status. Access to flush toilets was reported by
<14% of subjects and was very rare in rural areas (2.3%).
Between 25% and 40% of all subjects reported them-
selves to be unemployed, and about 60% said they were
much or somewhat poorer than most in their commu-
nity. ART subjects were twice as likely as HBC subjects
to have completed secondary school or higher (23% vs.
12% in urban areas, 11% vs. 5% in rural areas).
We found that subjects in urban areas were more
likely to report being able to speak English well and
report a high level of education compared with rural
areas. Females were more likely to be in the 20-29 age
range than males (23.6% vs. 13.9%, respectively) and to
be widowed than men (25.3% vs. 10.9%, respectively)
They were also less likely to have completed secondary
school or higher (8.9% vs. 19.7%, respectively), speak
English well (11.9% vs. 22.5%, respectively), or be the
main provider of food in the household (45.2% vs.
80.0%, respectively). The differences persisted even
when stratified by study group (ART vs. HBC).
Transportation, cost of seeking treatment
Table 2 shows differences between the study groups in
terms of transportation to the clinic, costs of seeking
treatment, and perceptions of care at the HIV clinic by
rural/urban status. While only 16% of subjects overall
reported that it would be very difficult for them to get
to an ART clinic, HBC subjects were 50% more likely to
report this difficulty than those on ART (RR: 1.48; 95%
CI: 1.07-2.05).
When asked to describe the transport they use (or
would use) to get to the HIV clinic, all forms of trans-
port other than walking (taxi, private car, bicycle and
bus) were less frequently mentioned by HBC subjects,
though this differed by location. All forms of transport
other than walking were reported by <15% of the popu-
lation, except for bicycles in the rural areas.
Overall, HBC participants were 40% to 55% less likely
to take a taxi (0.61; 95% CI: 0.35-1.04), a bicycle (RR:
0.45; 95% CI: 0.28-0.72) or a bus (RR: 0.48; 95% CI:
0.28-0.81) as part of their journeys, but these differed by
location. In rural areas, HBC patients were much less
likely to report that they would use a bicycle (10.5% vs.
24.5%, RR: 0.43; 95% CI: 0.27-0.69) or a bus (0.5% vs.
9.0%, RR: 0.06; 95% CI: 0.01-0.41) than those in the
ART group, but only minor differences were observed
in these modes in the urban areas. In urban areas, HBC
patients were much less likely to report they would use
a taxi (6.5% vs. 13.5%, RR: 0.48; 95% CI: 0.26-0.91) than
those in the ART group.
Cost barriers for HBC patients also differed by loca-
tion. About 25% of all subjects reported that they would
need to pay a fee to travel to a clinic, but in urban
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Table 1 Demographic characteristics of subjects in a cross-sectional survey in rural and urban areas of Zambia*
Demographic characteristics Urban: n (%) Rural: n (%)
ARVs
(N = 200)
HBC
(N = 200)
ARVs
(N = 200)
HBC
(N = 200)
Female 129 (65) 122 (61) 133 (67) 121 (61)
Age
<30 52 (26) 52 (26) 33 (16) 29 (15)
30.0 - 39.9 89 (45) 68 (34) 83 (42) 85 (42)
40.0 - 49.9 44 (22) 30 (15) 72 (36) 47 (23)
50.0 - 59.9 12 (6) 32 (16) 8 (4) 18 (9)
60.0+ 3 (2) 18 (9) 2 (1) 18 (9)
Missing 0 (0) 0 (0) 2 (1) 3 (2)
Marital status
Single 31 (16) 28 (14) 25 (13) 28 (14)
Engaged/married 110 (55) 94 (47) 106 (53) 126 (63)
Widowed/divorced/separated 59 (30) 78 (39) 69 (35) 46 (23)
Common language used
Nyanja 59 (30) 65 (33) 21 (11) 18 (9)
Bemba 44 (22) 29 (15) 20 (10) 12 (6)
Tonga 28 (14) 37 (18) 101 (51) 103 (51)
Lozi 41 (21) 33 (17) 15 (8) 10 (5)
Others 28 (14) 36 (17) 43 (22) 57 (28)
Educational level
Never attended school 11 (6) 18 (9) 10 (5) 22 (11)
Attended/completed primary school 84 (42) 87 (44) 99 (50) 127 (64)
Attended secondary school 59 (29) 71 (35) 69 (34) 40 (20)
Completed secondary school 36 (18) 23 (11) 18 (9) 6 (3)
Attended/completed tertiary education 10 (5) 1 (1) 4 (2) 5 (2)
Ability to communicate in English
Very well 58 (29) 27 (14) 23 (12) 18 (9)
Somewhat 73 (36) 88 (43) 104 (52) 69 (34)
Not able to 68 (34) 85 (43) 73 (37) 113 (57)
Missing 1 (1) 0 (0) 0 (0) 0 (0)
Respondents’ most important economic activity
Formal employment 26 (13) 19 (9) 26 (13) 25 (12)
Self-employed 95 (47) 85 (42) 114 (57) 105 (52)
Unemployed 71 (36) 77 (39) 47 (24) 53 (27)
Other 8 (4) 19 (10) 13 (6) 16 (8)
Missing 0 (0) 0 (0) 0 (0) 1 (1)
Self-reported economic status
Much or somewhat poorer than most 97 (48) 133 (66) 108 (54) 124 (62)
About the same as most 84 (42) 61 (30) 68 (34) 57 (28)
Somewhat or much wealthier than most 18 (9) 5 (2) 24 (12) 18 (9)
Missing 1 (1) 1 (1) 0 (0) 1 (1)
Health-seeking decisions made primarily by:
Self 100 (50) 96 (48) 114 (57) 127 (63)
Parents 32 (16) 25 (13) 31 (15) 17 (9)
Spouse 31 (16) 24 (12) 36 (18) 43 (21)
Others 37 (18) 55 (27) 19 (10) 12 (6)
Missing 0 (0) 0 (0) 0 (0) 1 (1)
Primary source of money for buying household food
Respondent (self) 110 (55) 102 (51) 125 (62) 127 (63)
Parents 17 (8) 13 (6) 25 (13) 5 (2)
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areas, HBC subjects were nearly three times more likely
to report believing this than those on ART (RR: 2.84;
95% CI: 2.02-3.98), with no difference in the rural areas.
This effect was almost entirely among men (male HBC
vs. ART patients: RR 14.1; 95% CI: 1.89-105; females
1.08; 95% CI: 0.50-2.36). In rural areas, HBC patients
were more likely to report needing to pay costs other
than transport and clinic fees than those on ART (13.6%
vs. 3.0%, RR: 4.52; 95% CI: 1.91-10.7). These patients
answered yes to the question, “Are there any other costs
that you must pay to obtain treatment for HIV/AIDS,
either in money, time, lost income, or anything else,
that have not been mentioned yet?”.
Most of this association was among women (male
HBC vs. ART patients: 1.18; 95% CI: 0.51-2.71; female
HBC vs. ART patients: 4.33; 95% CI: 1.65-11.4). HBC
subjects were not more likely to report needing to
spend a night away from home than those on ART
(1.4% vs. 1.2%), regardless of location, suggesting that
while those on ART might live closer to the clinic, the
differences were not so great that the journey could not
be completed in a day.
While very uncommon overall (5%), in urban areas,
HBC participants were twice as likely to report believing
that they would have to pay a fee at the clinic than
those on ART (RR: 9.50; 95% CI: 2.24-40.3) and that
they would have to pay someone to take over their tasks
to attend the clinic (RR: 2.45; 95% CI: 1.25 - 4.81).
Nearly 30% of those in the HBC programme reported
believing that they would need to attend the clinic more
than once per month, nearly three times more than
those on ART in rural areas (RR: 2.49; 95% CI: 1.54-
4.05) and roughly six times more than those on ART in
urban areas (RR: 6.21; 95% CI: 2.47-5.37). While about
10% of HBC subjects reported that they could not leave
work to seek ARVs, this was substantially more than
ARV recipients in both rural and urban areas (RR: 1.83;
95% CI: 1.10-3.04).
Perceptions about care and ARVs
In response to questions about subjects’ perceptions of
the ART clinic services, HBC subjects reported less
favourable impressions than those who had actually
experienced the care (Table 2), with little variation by
location or gender. Nearly 70% of subjects in both
groups felt the convenience of the clinic was good or
excellent, and about 20% in both groups felt the waiting
times were good or excellent. However, on all other
Table 1: Demographic characteristics of subjects in a cross-sectional survey in rural and urban areas of Zambia*
(Continued)
Spouse 46 (23) 35 (18) 39 (20) 58 (29)
Other 27 (14) 50 (25) 11 (5) 9 (5)
Missing 0 (0) 0 (0) 0 (0) 1 (1)
Frequency of going without a meal
Usually/always 54 (27) 14 (7) 28 (14) 31 (15)
Sometimes 114 (57) 133 (66) 109 (55) 92 (46)
Seldom/almost never 32 (16) 53 (27) 63 (32) 76 (38)
Missing 0 (0) 0 (0) 0 (0) 1 (1)
Household source of drinking water
Tap inside the house 13 (7) 5 (2) 2 (1) 6 (3)
Own tap outside the house 73 (37) 70 (35) 8 (4) 12 (6)
Shared community source 111 (56) 124 (62) 186 (94) 176 (88)
Other 3 (2) 1 (0) 4 (2) 5 (2)
Missing 0 (0) 0 (0) 0 (0) 1 (1)
Type of sanitary facility
Flush toilet 64 (32) 37 (18) 5 (3) 4 (2)
Traditional pit latrine 111 (56) 116 (58) 161 (81) 114 (57)
Ventilated improved pit latrine 12 (6) 22 (11) 3 (2) 0 (0)
None 13 (7) 25 (13) 31 (16) 80 (40)
Missing 0 (0) 0 (0) 0 (0) 2 (1)
Households reported to have or own
Electricity 97 (49) 47 (24) 10 (5) 11(5)
Cellular phone 144 (72) 99 (50) 79 (40) 56 (28)
Radio 135 (68) 94 (47) 125 (63) 96 (48)
Television 115 (58) 77 (39) 24 (12) 30 (15)
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indicators (including service, provider time, counselling
and staff concern), HBC subjects perceived the services
to be worse than did ART subjects.
Fear of attending the clinic was very common (Table 3)
in all locations, with more HBC subjects than ART
subjects reporting being afraid to go to the clinic (RR:
3.61; 95% CI: 2.80-4.66) and that if they went to the
clinic, people would not like them (RR: 2.28; 95% CI:
1.82-2.87). Concerns about fear and stigma were also
relatively common (Table 3), with 20% to 30% of all par-
ticipants reporting some concern about stigma, but were
much more common among HBC participants.
About 5% of HBC subjects reported that a family
member did not want them to take ARVs, but in the
rural areas, substantially more HBC subjects reported this
concern than ARV subjects in the rural areas (9.6% vs.
2.5%; RR: 3.84; 95 CI: 1.46-10.1). In most cases, reports
of stigma comparing male HBC patients and male ART
patients showed similar associations to those comparing
female HBC patients and female ART patients. The one
important exception to this was that we observed a
somewhat greater association between being in the HBC
group versus the ART group in terms of reported fear of
abuse when we compared only females (RR female HBC
vs. female ART: 1.82; 95% CI: 1.27-2.61) versus when we
compared only males (RR male HBC vs. male ART: 1.40;
95% CI: 0.80-2.45).
Most subjects, regardless of study group, identified
benefits of ARVs (Table 3). Both groups were equally
likely to report that ART would make them feel better
(a common belief) and that they would be happier if
they took ART. In urban areas, however, the HBC
group was somewhat less likely to report they would be
better able to take care of their families if they took
ART compared with the urban ART group (RR: 0.69;
95% CI: 0.49-0.97).
HBC subjects were much more likely than ART sub-
jects to report concerns about the harms of or difficul-
ties with ARVs. In particular, 27% of HBC subjects, but
only 13% of ART subjects, reported not having enough
food to take ARVs being a concern for initiating ART
(RR: 2.03; 95% CI: 1.51-2.73), with similar associations
being observed in both rural and urban areas. While
13% of ART subjects reported believing that they would
die if they took ARVs when they were making the deci-
sion whether or not to initiate ART, 38% of HBC sub-
jects reported this concern (RR: 2.98; 95% CI: 2.23-3.99).
The association was stronger for males comparing HBC
patients and ART patients (RR: 4.03; 95% CI: 2.25-7.21)
than for females (RR: 2.66; 95% CI: 1.89-3.72).
HBC subjects were much more likely to report feeling
they did not need ARVs because they were not sick
than those on ARVs (5.3% vs. 0.3% respectively),
although it was uncommon overall and was observed
almost entirely in the urban areas. In urban areas, HBC
subjects were also more likely than those on ART to
report that ARVs would make them sick (RR: 1.89; 95%
CI: 1.21-2.94). While only 2.3% of ARV subjects
reported a preference for traditional medicines over
ARVs at the time of making their decision to initiate
ART, 10.2% of HBC participants reported this prefer-
ence (RR: 4.35; 95% CI: 2.12-8.90), with hardly any dif-
ferences by location.
Discussion
In the early years of public treatment programmes in
sub-Saharan Africa, numbers of new patients initiating
ART grew exponentially, and demand exceeded the sup-
ply of treatment slots available. Rationing of treatment
by providers was necessary, but eligible patients also
rationed care implicitly through their decisions about
whether, and when, to seek treatment. As clinic capacity
continues to expand, patient self-selection into ART
programmes will be become increasingly important in
determining how close countries can come to the goal
of universal access programmes. Reaching universal
access will require increasing access to patients who
currently are eligible for ART, but are either unable or
unwilling to seek it. Designing effective interventions to
reduce barriers to access requires that we understand
these patients’ reasons for avoiding treatment.
We interviewed 400 people who were presumed eligi-
ble as they were in palliative care for HIV/AIDS and
had not initiated ARVs. This suggests that while HBC
caregivers are able to recognize their illnesses, they are
not able to get these patients into care. The most recent
Zambian Demographic and Health Survey found that
among adults aged 15 to 49, while 82% knew that a
healthy person could be HIV positive, only 39% of
women and 22% of men had ever tested for HIV [2].
Taken together, this suggests that while attitudes
towards HIV may be changing as ART becomes more
widely available, many still choose never to acknowledge
their status, and referral systems designed to move peo-
ple from knowledge of the problem to awareness of
their own status and on to enrolment in care and treat-
ment must be strengthened.
We found that HBC subjects perceived they would
face greater costs to seeking ART, both in terms of
direct payment for care and in the costs of travelling to
the clinic and the opportunity costs of seeking care.
This is similar to qualitative findings from Tanzania
[14], Zambia [15] and Malawi [16]. A recent cross-sec-
tional survey in Cameroon [23] found that those on
ART were of higher socio-economic status than those
eligible for ART but not on it.
While removing user fees has been shown to be effec-
tive at increasing adherence [24], these studies and our
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results suggest that efforts to get those who could bene-
fit from ARVs into care will have to find ways to reduce
the perceived and actual costs of accessing care beyond
the removal of clinic fees.
Interestingly, our study found differences in urban and
rural setting in the types of financial barriers faced by
those not on ART. Urban HBC patients were more
likely to report believing that they would face transport
and clinic cost barriers, while rural HBC patients per-
ceived that they would face more non-transport cost
barriers if they accessed care. This suggests that strate-
gies like providing transport vouchers or using mobile
clinics to deliver ARVs may be able to reduce these bar-
riers. However, our findings make it clear that the bar-
riers experienced in accessing ART in rural and urban
areas differ, and that in order to effectively reduce bar-
riers to care, interventions will need to be tailored to
the specific needs of the population.
We found that HBC patients also had substantially
greater negative perceptions about ART than those on
ART, and these negative perceptions were common,
regardless of the study site. Most subjects, regardless of
which group they were in, recognized the survival bene-
fits of ARVs, regardless of location. This suggests that
efforts to educate the public about HIV/AIDS treatment
have succeeded in conveying information. They have
been less successful in overcoming actual and perceived
barriers to action, however, as indicated by our survey.
Some misperceptions about ARVs were more com-
mon among the HBC population in our study and
reports of stigma were common. More than 50% of
HBC subjects said that they were afraid to go to the
HIV clinic. We found no important differences in
stigma across the rural and urban sites, regardless of the
measure used. Stigma and fear of violence has been pre-
viously identified as a barrier to accessing care
[14,18,19,25,26]. Our results suggest that even as access
to care has become more common, stigma has not dis-
appeared and continues to play a strong role in the deci-
sion-making process around ARVs.
Reports of concerns over stigma were common among
all subjects in our study (nearly 30% of the total popula-
tion mentioned that stigma had been experienced), but
were more common among those in the HBC pro-
gramme. In absolute terms, depending on the measure
used, those in the HBC group had between 20% and
40% more subjects reporting stigma than those in the
ART group. Two examples of this were: “I am afraid to
go to the ARV clinic” (54% vs. 15%); and “If I go to the
clinic people will not like me” (46% vs. 20%). Stigma
was the single strongest predictor of not being in care
in absolute terms, and this suggests that more work
needs to be done to remove feelings of stigma in the
community.
Concern about needing additional food intake upon
initiating ART has also previously been identified as a
barrier to ART initiation [14,27,28]. We were able to
quantify the increase compared with subjects on ART
and found that HBC subjects were three times more
likely to report concerns about not having enough food
to take ARVs than those on ARVs. We found that this
association between not being on ART and concerns
about food held true in both rural and urban areas and
among both men and women, suggesting that this may
be a barrier experienced by many subpopulations of
HIV-infected ART eligible patients.
We cannot tell from our data whether those in the HBC
group were less able to access food or whether those on
ART were better able to access food after initiating ART
because they were able to return to work. However, provi-
sion of food to those in care could help increase a willing-
ness to initiate care, although it would also increase costs,
be difficult to sustain over time and may pose ethical
issues in communities where food insecurity is common.
Our study had several strengths. We interviewed
800 subjects, which allowed us to conduct one of the
largest and most comprehensive analyses of barriers to
ART care that yet exists. We also included both rural
and urban sites within Zambia, which helped improve
the generalizability of our findings. Future efforts to
determine how barriers and facilitators to accessing
ARVs differ across rural and urban areas will help to
further target interventions to reduce such barriers.
While our study was able to determine some key bar-
riers to accessing care, it had several limitations. First,
our target sample was not limited to subjects who were
known to be HIV infected and eligible for ART, and
who opted out of treatment. We felt it would be prohi-
bitively difficult to identify these subjects and therefore
chose a sample of HBC subjects believed by HBC care-
givers to be eligible for, but not on, ART. Some subjects
in this group may not have been eligible for ART, and it
is also possible that HBC caregivers mistook some ill-
nesses for HIV/AIDS.
It is not clear what impact this would have had on our
findings, but we note that there was little difference in
our results when the analysis was limited to subjects
who told us they had actively made the decision not to
initiate ART. In addition, patients in HBC care are likely
to have had counselling about HIV and ART from the
HBC caregivers. This would likely have the effect of
making the two populations more similar with respect
to their attitudes towards ART. Thus our findings
should be interpreted as conservative estimates of the
magnitude of the barriers to ART.
Second, we relied on subject recall of their concerns
about initiating ART. Using this approach, we could not
tell the difference between actual and perceived barriers
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to care seeking. In addition, for those who had not
actively made a decision to forgo ART, we had to ask
about what those in their community felt were concerns
about ART. Inevitably, some recall bias results when
this approach is used. Those on ART, particularly those
having a positive experience, would be less likely to
report serious barriers to care seeking. While we could
not remove this bias completely, we sought to mitigate
it by asking subjects who had initiated ART to recall
their concerns at the time they were making the deci-
sion whether or not to initiate care.
Conclusions
In conclusion, we found that patients in home-based
care for HIV/AIDS who never initiated ART experi-
enced greater perceived financial and logistical barriers
to seeking HIV care than those on ART. They were
more likely to identify concerns about needing food if
they initiated ART, costs for transportation and care,
negative attitudes towards ARVs, and stigma as com-
mon concerns about seeking treatment. Future efforts to
expand access to ARV care should consider ways to
reduce these barriers in order to encourage more of
those medically eligible for ARVs to initiate care.
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